Experimental triple-hormone therapy achieved up to 24.2% weight loss in Phase 2 trials, but it remains under investigation and is not yet FDA approved.
The revised GATE 2027 Biotechnology syllabus expands coverage across molecular biology, immunology, genomics, bioinformatics, and other emerging areas of biotechnology